Suppr超能文献

在无抗血小板药物情况下评估血小板功能时出现假结果的风险:PFA-100、多板电阻抗聚集测定法和 verify now 检测法的比较。

The risk of false results in the assessment of platelet function in the absence of antiplatelet medication: comparison of the PFA-100, multiplate electrical impedance aggregometry and verify now assays.

机构信息

Department of Cardiology, Koşuyolu Heart & Research Hospital, Istanbul, Turkey.

出版信息

Thromb Res. 2010 Apr;125(4):e132-7. doi: 10.1016/j.thromres.2009.11.005. Epub 2009 Dec 1.

Abstract

OBJECTIVES

Evaluation of aspirin (ASA) responsiveness with platelet function tests varies by the choice of blood mixture and functional test and cut off values for defining the the treatment used. Addition to that we also aimed to determine agreement between three tests and to research whether there is any necessity to measure baseline platelet activity.

METHODS

The study group comprised of 52 patients with multiple risk factors receiving primary prophylaxis of ASA (100 mg/day). For each patient inhibition of platelet aggregation with aspirin was determined using three different whole blood tests: Multiplate electrical impedance aggregometry, Verify Now Aspirin, and collagen-epinephrine closure time PFA-100. Platelet aggregation was assessed with multiplate electrical impedance aggregometry,and was defined as the area under curve (AUC,AUxmin). Maximal 6,4 microM collagen-induced AUC were used to quantify platelet aggregation due to ASA. The ASA response was defined as >30 % reduction in basal platelet aggregation with multiplate electrical impedance aggregometry. Collagen induced platelet aggregation at the Verify Now Aspirin assay quantitated the ASA-induced platelet inhibition as aspirin reaction units (ARU). According to manufacturer insert ARU>550 indicates aspirin resistance. ASA platelet function studies were assessed twice at baseline (pre-aspirin), and after 7 day(post-aspirin) were performed.

RESULTS

After ASA intake none of the patients was found aspirin resistant with PFA-100. (CEPI-CT (129+/-36 vs 289+/-18 ). None of the patients was found aspirin resistant with PFA-100. As>30 % reduction in basal platelet aggregation with multiplate electrical impedance aggregometry is selected all of the patients have been stratified as responders.(COL TEST 688+/-230 vs 169+/-131 AU) None of the patients with Verify Now Aspirin found resistance to ASA(594+/-62 vs 446+/-43).Prior to ASA intake 15 of all patients with VN(501+/-16) and 2 of all patients with multiplate electrical impedance aggregometry (223+/-40 AUC )aggregation levels below the cut off label before ingestion of ASA.None of the patients was above the cut off label with PFA -100 (129+/-36).

CONCLUSIONS

Verify Now ASA assay, multiplate electrical impedance aggregometry and PFA-100 seem to be reliable tests in reflecting ASA effect on platelets. Cut off labels for the defining the responsiveness given by manufacturer may show significant interindividual variability with Verify Now ASA assay and multiplate electrical impedance aggregometry, and these test may show platelet inhibition despite the absence of ASA intake. Consideration of the pretreatment values may eliminate the risk of overestimation in the assessment of platelet inhibition by ASA.

摘要

目的

使用血小板功能检测评估阿司匹林(ASA)反应性因血液混合和功能检测选择以及定义治疗用途的截断值而有所不同。除此之外,我们还旨在确定三种检测之间的一致性,并研究是否有必要测量基线血小板活性。

方法

该研究组包括 52 名患有多种危险因素的患者,他们正在接受 ASA(100mg/天)的一级预防。对每位患者使用三种不同的全血检测来确定阿司匹林抑制血小板聚集的情况:Multiplate 电阻抗聚集仪、VerifyNow Aspirin 和胶原-肾上腺素闭合时间 PFA-100。使用 Multiplate 电阻抗聚集仪评估血小板聚集,并定义为曲线下面积(AUC、AUxmin)。由于 ASA 引起的最大 6.4µM 胶原诱导的 AUC 用于量化血小板聚集。ASA 反应性定义为 Multiplate 电阻抗聚集仪检测到的基础血小板聚集减少≥30%。VerifyNow Aspirin 检测中胶原诱导的血小板聚集定量表示 ASA 诱导的血小板抑制作用,单位为阿司匹林反应单位(ARU)。根据制造商的插入说明,ARU>550 表示阿司匹林抵抗。在基线(阿司匹林前)和 7 天后(阿司匹林后)进行两次 ASA 血小板功能研究。

结果

在服用 ASA 后,没有患者在 PFA-100 检测中显示阿司匹林抵抗。(CEPI-CT(129±36 与 289±18)。没有患者在 PFA-100 检测中显示阿司匹林抵抗。由于 Multiplate 电阻抗聚集仪检测到基础血小板聚集减少≥30%,所有患者均被分类为反应者。(COLTEST 688±230 与 169±131 AU)。在 VerifyNow Aspirin 检测中,没有患者对 ASA 产生抵抗(594±62 与 446±43)。在服用 ASA 之前,所有接受 VN(501±16)和所有接受 Multiplate 电阻抗聚集仪(223±40 AUC)检测的患者中,有 15%和 2%的患者在服用 ASA 前的聚集水平低于标签规定值。在 PFA-100 检测中,没有患者的检测值高于标签规定值(129±36)。

结论

VerifyNow ASA 检测、Multiplate 电阻抗聚集仪和 PFA-100 似乎是可靠的检测方法,可反映 ASA 对血小板的作用。制造商给出的定义反应性的截断值可能会在 VerifyNow ASA 检测和 Multiplate 电阻抗聚集仪检测中显示出显著的个体间差异,并且这些检测可能会显示血小板抑制作用,尽管没有服用 ASA。考虑治疗前值可以消除在评估 ASA 抑制血小板方面的高估风险。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验